Acceleron Pharma

Acceleron is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to treat serious and rare diseases. The Company's research focuses on harnessing the power of the TGF-beta protein superfamily, the target-rich area of biology behind the body’s capacity for cellular growth and repair. The Company’s lead product candidate, luspatercept, is being evaluated in two Phase 3 studies in a global partnership with Celgene to treat chronic, sometimes debilitating anemias in myelodysplastic syndromes (MDS) and beta-thalassemia. Acceleron is also advancing clinical programs in neuromuscular disorders and cancer, and preclinical research in fibrotic and other diseases.

Company Growth (employees)
Cambridge, US
Size (employees)
121 (est)
Acceleron Pharma was founded in 2003 and is headquartered in Cambridge, US

Key People/Management at Acceleron Pharma

Habib Dable

Habib Dable

President and Chief Executive Officer
Kevin McLaughlin

Kevin McLaughlin

Chief Financial Officer
Steven Ertel

Steven Ertel

Chief Operating Officer
Matthew Sherman

Matthew Sherman

Chief Medical Officer
Ravi Kumar

Ravi Kumar

Chief Scientific Officer
John Quisel

John Quisel

SVP, Business Development and General Councel
Christopher Rovaldi

Christopher Rovaldi

VP, Program Management

Acceleron Pharma Office Locations

Acceleron Pharma has an office in Cambridge
Cambridge, US (HQ)
128 Sidney Street
Show all (1)

Acceleron Pharma Financials and Metrics

Acceleron Pharma Financials

Acceleron Pharma's revenue was reported to be $27.8 m in FY, 2016

Revenue (Q2, 2017)

3.1 b

Net income (Q2, 2017)

(29.7 b)

EBIT (Q2, 2017)

(29.9 b)

Market capitalization (16-Feb-2018)

1.7 b

Cash (30-Jun-2017)

30.7 m
Acceleron Pharma's current market capitalization is $1.7 b.
USDFY, 2013FY, 2014FY, 2015FY, 2016


57.2 m14.6 m18.1 m27.8 m

Revenue growth, %


R&D expense

68.6 m

General and administrative expense

25.3 m
USDQ1, 2014Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017


3.3 m5.7 m4.2 m18.2 m3.2 m3 m3.7 m3.1 b

R&D expense

11.8 m14.2 m13.3 m16.2 m16.1 m17.1 m21.7 m21.6 b

General and administrative expense

3.8 m4.7 m5.4 m5.9 m6.7 m6.4 m7.8 m11.4 b

Operating expense total

15.5 m18.8 m18.8 m22.2 m22.9 m23.5 m29.6 m33 b
USDFY, 2013FY, 2014FY, 2015FY, 2016


113.2 m176.5 m27.8 m21 m

Accounts Receivable

11.5 m


2.2 m2.5 m2.5 m3.9 m

Current Assets

119 m182.3 m110.9 m146.8 m
USDQ1, 2014Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017


214.1 m43.4 m63.7 m37 m31 m33.2 m30.7 m

Current Assets

218.5 m122.4 m170.7 m127 m145 m149 m148.4 m


3.7 m2.9 m3.7 m4.2 m4.2 m7.1 m7.2 m

Total Assets

223 m158.4 m289.6 m274.2 m262.9 m229.1 m208.5 m
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(21.9 m)(51.3 m)(63.9 m)(57 m)

Depreciation and Amortization

915 k1.1 m1.2 m1.7 m


(823 k)(255 k)7 k(1.4 m)

Accounts Payable

(53 k)(161 k)151 k644 k
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(9.1 m)(10.4 m)(11.9 m)5.1 m(22 m)(25.4 m)

Accounts Payable

891 k2.6 m3.3 m1.6 m1.8 m2.6 m1.2 m566 k2.1 m911 k
Y, 2017

Financial Leverage

1.1 x
Show all financial metrics

Acceleron Pharma Operating Metrics

FY, 2015FY, 2016

Phase III Trials

Show all operating metrics

Acceleron Pharma Market Value History

Acceleron Pharma's Web-traffic and Trends

Acceleron Pharma Online and Social Media Presence

Acceleron Pharma Company Life and Culture

You may also be interested in